y 26763 has been researched along with clofilium in 1 studies
| Studies (y 26763) | Trials (y 26763) | Recent Studies (post-2010) (y 26763) | Studies (clofilium) | Trials (clofilium) | Recent Studies (post-2010) (clofilium) |
|---|---|---|---|---|---|
| 33 | 0 | 4 | 140 | 1 | 21 |
| Protein | Taxonomy | y 26763 (IC50) | clofilium (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.0813 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okamoto, K; Sakuta, H; Watanabe, Y | 1 |
1 other study(ies) available for y 26763 and clofilium
| Article | Year |
|---|---|
Antiarrhythmic drugs, clofilium and cibenzoline are potent inhibitors of glibenclamide-sensitive K+ currents in Xenopus oocytes.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzopyrans; Electrophysiology; Female; Glyburide; Imidazoles; Membrane Potentials; Oocytes; Potassium Channels; Pyridines; Quaternary Ammonium Compounds; Xenopus laevis | 1993 |